Therapeutic Potential of Oligo-Fucoidan in Mitigating Peritoneal Dialysis-Associated Fibrosis
Peritoneal dialysis (PD) serves as a home-based kidney replacement therapy with increasing utilization across the globe. However, long-term use of high-glucose-based PD solution incites repeated peritoneal injury and inevitable peritoneal fibrosis, thus compromising treatment efficacy and resulting...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Marine Drugs |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1660-3397/22/12/529 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850036807630061568 |
|---|---|
| author | Yu-Wei Chen Mei-Yi Wu Nai-Jen Huang Mai-Szu Wu Yung-Ho Hsu Chia-Te Liao Cheng-Hsien Chen |
| author_facet | Yu-Wei Chen Mei-Yi Wu Nai-Jen Huang Mai-Szu Wu Yung-Ho Hsu Chia-Te Liao Cheng-Hsien Chen |
| author_sort | Yu-Wei Chen |
| collection | DOAJ |
| description | Peritoneal dialysis (PD) serves as a home-based kidney replacement therapy with increasing utilization across the globe. However, long-term use of high-glucose-based PD solution incites repeated peritoneal injury and inevitable peritoneal fibrosis, thus compromising treatment efficacy and resulting in ultrafiltration failure eventually. In the present study, we utilized human mesothelial MeT-5A cells for the in vitro experiments and a PD mouse model for in vivo validation to study the pathophysiological mechanisms underneath PD-associated peritoneal fibrosis. High-glucose PD solution (Dianeal 4.25%, Baxter) increased protein expression of mesothelial–mesenchymal transition (MMT) markers, such as N-cadherin and α-SMA in MeT-5A cells, whereas it decreased catalase expression and stimulated the production of reactive oxygen species (ROS). Furthermore, macrophage influx and increased serum pro-inflammatory cytokines, such as IL-1β, MCP-1, and TNF-α, were observed in the PD mouse model. Interestingly, we discovered that oligo-fucoidan, an oligosaccharide extract from brown seaweed, successfully prevented PD-associated peritoneal thickening and fibrosis through antioxidant effect, downregulation of MMT markers, and attenuation of peritoneal and systemic inflammation. Hence, oligo-fucoidan has the potential to be developed into a novel preventive strategy for PD-associated peritoneal fibrosis. |
| format | Article |
| id | doaj-art-e7d62dad39934ef28a6e030ceb728668 |
| institution | DOAJ |
| issn | 1660-3397 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Marine Drugs |
| spelling | doaj-art-e7d62dad39934ef28a6e030ceb7286682025-08-20T02:57:02ZengMDPI AGMarine Drugs1660-33972024-11-01221252910.3390/md22120529Therapeutic Potential of Oligo-Fucoidan in Mitigating Peritoneal Dialysis-Associated FibrosisYu-Wei Chen0Mei-Yi Wu1Nai-Jen Huang2Mai-Szu Wu3Yung-Ho Hsu4Chia-Te Liao5Cheng-Hsien Chen6Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanDivision of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235041, TaiwanDepartment of Internal Medicine, Division of Nephrology, Wan Fang Hospital, Taipei Medical University, Taipei 116, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanDivision of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235041, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanPeritoneal dialysis (PD) serves as a home-based kidney replacement therapy with increasing utilization across the globe. However, long-term use of high-glucose-based PD solution incites repeated peritoneal injury and inevitable peritoneal fibrosis, thus compromising treatment efficacy and resulting in ultrafiltration failure eventually. In the present study, we utilized human mesothelial MeT-5A cells for the in vitro experiments and a PD mouse model for in vivo validation to study the pathophysiological mechanisms underneath PD-associated peritoneal fibrosis. High-glucose PD solution (Dianeal 4.25%, Baxter) increased protein expression of mesothelial–mesenchymal transition (MMT) markers, such as N-cadherin and α-SMA in MeT-5A cells, whereas it decreased catalase expression and stimulated the production of reactive oxygen species (ROS). Furthermore, macrophage influx and increased serum pro-inflammatory cytokines, such as IL-1β, MCP-1, and TNF-α, were observed in the PD mouse model. Interestingly, we discovered that oligo-fucoidan, an oligosaccharide extract from brown seaweed, successfully prevented PD-associated peritoneal thickening and fibrosis through antioxidant effect, downregulation of MMT markers, and attenuation of peritoneal and systemic inflammation. Hence, oligo-fucoidan has the potential to be developed into a novel preventive strategy for PD-associated peritoneal fibrosis.https://www.mdpi.com/1660-3397/22/12/529fibrosismesothelial–mesenchymal transitionMMToligo-fucoidanperitoneal dialysis |
| spellingShingle | Yu-Wei Chen Mei-Yi Wu Nai-Jen Huang Mai-Szu Wu Yung-Ho Hsu Chia-Te Liao Cheng-Hsien Chen Therapeutic Potential of Oligo-Fucoidan in Mitigating Peritoneal Dialysis-Associated Fibrosis Marine Drugs fibrosis mesothelial–mesenchymal transition MMT oligo-fucoidan peritoneal dialysis |
| title | Therapeutic Potential of Oligo-Fucoidan in Mitigating Peritoneal Dialysis-Associated Fibrosis |
| title_full | Therapeutic Potential of Oligo-Fucoidan in Mitigating Peritoneal Dialysis-Associated Fibrosis |
| title_fullStr | Therapeutic Potential of Oligo-Fucoidan in Mitigating Peritoneal Dialysis-Associated Fibrosis |
| title_full_unstemmed | Therapeutic Potential of Oligo-Fucoidan in Mitigating Peritoneal Dialysis-Associated Fibrosis |
| title_short | Therapeutic Potential of Oligo-Fucoidan in Mitigating Peritoneal Dialysis-Associated Fibrosis |
| title_sort | therapeutic potential of oligo fucoidan in mitigating peritoneal dialysis associated fibrosis |
| topic | fibrosis mesothelial–mesenchymal transition MMT oligo-fucoidan peritoneal dialysis |
| url | https://www.mdpi.com/1660-3397/22/12/529 |
| work_keys_str_mv | AT yuweichen therapeuticpotentialofoligofucoidaninmitigatingperitonealdialysisassociatedfibrosis AT meiyiwu therapeuticpotentialofoligofucoidaninmitigatingperitonealdialysisassociatedfibrosis AT naijenhuang therapeuticpotentialofoligofucoidaninmitigatingperitonealdialysisassociatedfibrosis AT maiszuwu therapeuticpotentialofoligofucoidaninmitigatingperitonealdialysisassociatedfibrosis AT yunghohsu therapeuticpotentialofoligofucoidaninmitigatingperitonealdialysisassociatedfibrosis AT chiateliao therapeuticpotentialofoligofucoidaninmitigatingperitonealdialysisassociatedfibrosis AT chenghsienchen therapeuticpotentialofoligofucoidaninmitigatingperitonealdialysisassociatedfibrosis |